Received Mar 19, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| TYP | TYPHOID LIVE ORAL TY21A (VIVOTIF) | BERNA BIOTECH, LTD. | 4 | Unknown | PO / MO |
Began refill of doxycycline; Case reference number US-BN-2025-001805 is a spontaneous case initially received from a consumer via Bavarian Nordic (reference number: CASE-000765) on 17-Nov-2025 and concerns a *64-year-old* female patient. The patient's medical history and concomitant medication details were not provided. On 15-Nov-2025, the patient *took first dose* of Vivotif vaccine (batch number: unknown) at unknown dose, *orally for typhoid prevention on trip to [withheld]*. On the next afternoon patient began refill of doxycycline. (explicitly coded as 'Contraindicated product administered'). *On 17-Nov-2025, the patient took second dose of Vivotif vaccine (batch number: unknown) at unknown dose, orally for typhoid prevention on trip to [withheld].* *On 19-Nov-2025, the patient took third dose of Vivotif vaccine (batch number: unknown) at unknown dose, orally for typhoid prevention on trip to [withheld].* *On 21-Nov-2025, the patient took fourth dose of Vivotif vaccine (batch number: unknown) at unknown dose, orally for typhoid prevention on trip to [withheld].* *At the time of the follow-up report, the patient did not experience any adverse events due to Vivotif. All follow-up information is blended into the case narrative above, with the latest information presented between asterisks (*). Follow up information received from consumer on 19-Dec-2025 via Bavarian Nordic: New information included patient demographics, Vivotif indication and new dosing regimens added. It was confirmed that the patient did not have any adverse events from Vivotif. Non-significant follow-up was received from the reporter on 27-Jan-2026. The reporter confirmed that the survey had already been completed and that there was no new information to report.; Reporter's Comments: This case concerns a 64-year-old female patient, started dosing regimen of Vivotif vaccine for an indication of typhoid prevention (on trip to [withheld]). On the next afternoon patient began refill of doxycycline, which is considered as contraindicated product administered. Patient did not experience any adverse events due to Vivotif. Contraindicated product administered is considered as listed per company convention. The patient's medical history and concomitant medication details were not provided. Contraindicated product administered is not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.; Sender's Comments: This case concerns a 64-year-old female patient, started dosing regimen of Vivotif vaccine for an indication of typhoid prevention (on trip to [withheld]). On the next afternoon patient began refill of doxycycline, which is considered as contraindicated product administered. Patient did not experience any adverse events due to Vivotif. Contraindicated product administered is considered as listed per company convention. The patient's medical history and concomitant medication details were not provided. Contraindicated product administered is not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.
Comments: None.
DOXYCYCLINE